SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients

European Journal of Cancer

Volumn 43, Issue 4, 2007, Pages 752-761

  Le Deley, Marie Cécile ^a   Guinebretière, Jean Marc ^b   Gentet, Jean Claude ^c   Pacquement, Hélène ^d   Pichon, Fabienne ^e   Marec Bérard, Perrine ^f   Entz Werlé, Natacha ^g   Schmitt, Claudine ^h   Brugières, Laurence ^a   Vanel, Daniel ^a   Dupoüy, Noëlle ^a   Tabone, Marie Dominique ⁱ   Kalifa, Chantal ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE RENÉ HUGUENIN   (France)

^c TIMONE HOSPITAL   (France)

^d INSTITUT CURIE   (France)

^e CENTRE OSCAR LAMBRET   (France)

^f CENTRE LÉON BÉRARD   (France)

^g HÔPITAL DE HAUTEPIERRE   (France)

^h CHU NANCY BRABOIS   (France)

ⁱ ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

Chemotherapy; Doxorubicin; Etoposide ifosfamide; Histologic response; Methotrexate; Osteosarcoma; Randomised trial

Indexed keywords

DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; MESNA; METHOTREXATE;

ADOLESCENT; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; FEMALE; FOLLOW UP; GLOMERULAR DYSFUNCTION; HAZARD RATIO; HEMATURIA; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OSTEOSARCOMA; PREOPERATIVE CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SINGLE BLIND PROCEDURE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBULAR DYSFUNCTION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; MALE; METHOTREXATE; OSTEOSARCOMA; PREOPERATIVE CARE;

EID: 33947710840     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.10.023     Document Type: Article

References (30)

1. Bacci G., Ferrari S., Bertoni F., et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 18 24 (2000) 4016-4027
2. Bielack S.S., Kempf-Bielack B., Delling G., et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20 3 (2002) 776-790
3. Link M.P., Goorin A.M., Miser A.W., et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314 25 (1986) 1600-1606
4. Rosen G., Caparros B., Huvos A.G., et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49 6 (1982) 1221-1230
5. Winkler K., Beron G., Kotz R., et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol 2 6 (1984) 617-624
6. Jaffe N., Paed D., Farber S., et al. Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Cancer 31 6 (1973) 1367-1373
7. Cortes E.P., Holland J.F., Wang J.J., and Sinks L.F. Doxorubicin in disseminated osteosarcoma. JAMA 221 10 (1972) 1132-1138
8. Ochs J.J., Freeman A.I., and Douglass Jr. H.O. et al. cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 62 2 (1978) 239-245
9. Harris M.B., Cantor A.B., Goorin A.M., et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol. 24 2 (1995) 87-92
10. Marti C., Kroner T., Remagen W., et al. High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep 69 1 (1985) 115-117
11. Kalifa C., Brunat-Mentigny M., Pacquement H., et al. Treatment of Osteosarcoma (OS) with an Intensive Chemotherapy Regimen (OS87 protocol). Med Pediatr Oncol 27 4 (1996) 251
12. Gentet J.C., Brunat-Mentigny M., Demaille M.C., et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Eur J Cancer 33 2 (1997) 232-237
13. Goorin A.M., Harris M.B., Bernstein M., et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 20 2 (2002) 426-433
14. Miser J.S., Kinsella T.J., Triche T.J., et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 5 8 (1987) 1191-1198
15. Huvos A.G., Rosen G., and Marcove R.C. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 101 1 (1977) 14-18
16. Rothman K.J. Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chronic Dis 31 8 (1978) 557-560
17. Wartelle M, Kramar A, Jan P, Kruger D. PIGAS: An interactive statistical database management system. Proceedings of the Second National Workshop on Statistical Database Management, 1983.
18. Pocock S.J. Size of cancer clinical trials and stopping rules. Br J Cancer 38 6 (1978) 757-766
19. Souhami R.L., Craft A.W., Van der Eijken J.W., et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 350 9082 (1997) 911-917
20. Meyers P.A., Gorlick R., Heller G., et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 16 7 (1998) 2452-2458
21. Meyers P.A., Schwartz C.L., Krailo M., et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23 9 (2005) 2004-2011
22. Smeland S., Muller C., Alvegard T.A., et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 39 4 (2003) 488-494
23. Winkler K., Beron G., Delling G., et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 6 2 (1988) 329-337
24. Desandes E., Lacour B., Sommelet D., et al. Cancer incidence among adolescents in France. Pediatr Blood Cancer 43 7 (2004) 742-748
25. Desandes E., Clavel J., Berger C., et al. Cancer incidence among children in France, 1990-1999. Pediatr Blood Cancer 43 7 (2004) 749-757
26. Bacci G., Forni C., Ferrari S., et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol 25 11 (2003) 845-853
27. Ferrari S., Smeland S., Mercuri M., et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A Joint Study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol (2005)
28. Le Deley M.C., Leblanc T., Shamsaldin A., et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 21 6 (2003) 1074-1081
29. Pratt C.B., Meyer W.H., Luo X., et al. Second malignant neoplasms occuring in survivors of osteosarcoma. Cancer 80 5 (1997) 960-965
30. Ferrari C., Bohling T., Benassi M.S., et al. Secondary tumors in bone sarcomas after treatment with chemotherapy. Cancer Detect Prev 23 5 (1999) 368-374